Abivax Falls on Short Seller's Carcinogenicity Allegations
Abivax shares fell 12.4% on November 20 after Scorpion Capital disclosed a short position and published a report alleging undisclosed carcinogenicity risks in obefazimod. Analyst consensus targets $16
Short Seller Targets Abivax Safety Ahead of NDA
NEW YORK, November 20 —
When Scorpion Capital Partners disclosed a short position in ABIVAX Société Anonyme (ABVX) and published a report alleging obefazimod carries undisclosed carcinogenicity risks, shares fell 12.4% on November 20. Analyst consensus targets sit more than double the trading price, leaving investors to judge whether a $6.28 billion valuation built entirely on one drug's regulatory approval has just developed a crack.
- ABVX ADRs fell 12.4% on November 20 after Scorpion Capital disclosed a short position and published its report.
- Scorpion alleges extreme lipophilicity comparable to banned pesticides and UVA absorption at 8.4 times the ICH photosafety threshold.
- Analyst consensus target is $163.58 versus Friday's $71.74; Abivax holds $400 million cash with no long-term debt.
The Carcinogenicity Argument Rests on Two Specific Claims
Scorpion Capital's report, disclosing a short position, centers on two laboratory findings about obefazimod, a compound Abivax has in Phase 3 for ulcerative colitis and Phase 2b for Crohn's disease, designed to stabilize the immune response without suppressing it. The first is extreme lipophilicity, a measure of how readily a compound accumulates in tissue, which Scorpion contends is comparable to banned pesticides and persistent organic pollutants. The second is UVA light absorption at 8.4 times the ICH photosafety threshold, raising what the report terms photocarcinogenicity risk. The allegations revive earlier market concerns about malignancy signals observed in obefazimod's clinical trials.
Analysts Had Been Trimming Before Friday
Abivax's clinical-stage structure means buy-side valuation is entirely probability-weighted. The $163.58 consensus target models an NDA approval and commercial launch that has not happened, the kind of terminal-value assumption familiar to anyone running a DCF model. Even before Scorpion's report, something was shifting: 2027 revenue consensus estimates fell from $188.8 million to $144.6 million in the 90 days into September 2026, as analysts cut probability weights. EPS has missed consensus in three of the last four quarters, the most recent by 97%, while the company burns roughly $197 million in operating cash annually against a $400 million cash balance.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| ABVX | $6.3B | n/a | -32.3% |
| CELC | $2.6B | n/a | -42.2% |
| PRAX | $8.4B | n/a | +83.1% |
| ALMS | $515M | n/a | -40.7% |
| TNGX | $3.7B | n/a | +126.4% |
| GPCR | $1.2B | n/a | -50.1% |
The NDA Review Is When the Allegations Actually Get Tested
Whether Scorpion's laboratory claims are correct or contested, Abivax's answer will come through regulatory channels. The NDA filing timeline remains undisclosed, and the report adds pressure to that uncertainty. Institutional investors hold 75.1% of the float; short interest stood at 4.8% ahead of Friday, skewing ownership toward holders with an approval-horizon time frame. The number to watch is any FDA response to the safety characterizations: if regulators request additional carcinogenicity studies or raise lipophilicity concerns in the NDA review, the analyst target gap compresses from opportunity to ceiling. Run the free ABIVAX Société Anonyme deep-dive for updated financials.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why did Abivax stock fall 12.4%?
Abivax shares fell 12.4% on November 20 after Scorpion Capital disclosed a short position and published a report alleging that obefazimod carries undisclosed carcinogenicity risks. The report cites extreme lipophilicity comparable to banned pesticides and UVA light absorption at 8.4 times the ICH photosafety threshold.
What is Scorpion Capital's allegation?
Scorpion Capital contends that obefazimod has extreme lipophilicity, a measure of how readily a compound accumulates in tissue, comparable to banned pesticides and persistent organic pollutants. The report also alleges photocarcinogenicity risk based on UVA light absorption findings.
What is obefazimod designed to treat?
Obefazimod is a compound in Phase 3 for ulcerative colitis and Phase 2b for Crohn's disease, designed to stabilize the immune response without suppressing it.
What do analysts think about Abivax?
Analyst consensus target is $163.58, more than double the Friday trading price of $71.74. Revenue consensus has been falling: 2027 estimates dropped from $188.8 million to $144.6 million over the 90 days into September 2026.
When will the FDA rule on the safety allegations?
Abivax's NDA filing timeline remains undisclosed. The FDA's response to the safety characterizations during the NDA review will determine whether the analyst target gap represents an opportunity or a ceiling.
Short-seller Scorpion Capital Partners disclosed a short position in Abivax on Friday and published a report alleging its Phase 3 ulcerative colitis drug obefazimod carries undisclosed carcinogenicity risks based on independent laboratory testing. The stock fell 12.4%, leaving analyst price targets more than double the current trading price — and investors to decide which side is right ahead of the drug's NDA filing.